# Evaluation of Cabozantinib in Metastatic Renal Cell Carcinoma (mRCC) With Brain Metastases

> **NCT03967522** · PHASE2 · COMPLETED · sponsor: **Centre Leon Berard** · enrollment: 26 (actual)

## Conditions studied

- Metastatic Renal Cell Carcinoma

## Interventions

- **DRUG:** Cabozantinib

## Key facts

- **NCT ID:** NCT03967522
- **Lead sponsor:** Centre Leon Berard
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-11-29
- **Primary completion:** 2024-10-22
- **Final completion:** 2024-11-01
- **Target enrollment:** 26 (ACTUAL)
- **Last updated:** 2025-08-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03967522

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03967522, "Evaluation of Cabozantinib in Metastatic Renal Cell Carcinoma (mRCC) With Brain Metastases". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT03967522. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*